Market Place
Sourcing Support
ImmVira`s MVR-T3011 IT Injection Receives FDA Fast Track Designation
15 Mar 2024 //
PR NEWSWIRE
MVR-T3011 IV Successfully Concludes Phase I Clinical Study
09 Nov 2023 //
PR NEWSWIRE
ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor
22 Aug 2023 //
PR NEWSWIRE
ImmVira presented clinical results of two proprietary products at ASCO 2023
06 Jun 2023 //
PR NEWSWIRE
ImmVira`s oncolytic product MVR-C5252 obtained NMPA`s approval for Trial
29 Mar 2023 //
PR NEWSWIRE
Intratumoral Injected OV Monotherapy Achieved Median PFS of 12.9 Months
08 Feb 2023 //
PR NEWSWIRE
ImmVira announced its signing of Series C+ financing with Investors
26 Oct 2022 //
PRNEWSWIRE
ImmVira`s MVR-C5252 Targeting Malignant Glioma Obtained FDA`s ODD
07 Aug 2022 //
PRNEWSWIRE
ImmVira`s IV administered oHSV MVR-T3011 IV demonstrated promising activities
20 Jul 2022 //
PRNEWSWIRE
ImmVira enters development in comb. therapy of MVR-T3011 IT and MEK inhibitor
19 Apr 2022 //
PRNEWSWIRE
ImmVira`s IV oncolytic virus product MVR-T3011 IV completed first dosing
01 Mar 2022 //
PRNEWSWIRE
ImmVira`s New-Gen Vector Poised to Enable CAR-T Treatment for Solid Tumors
24 Jan 2022 //
PRNEWSWIRE
ImmVira`s MVR-T3011 IV completed 2 cohorts dose-escalation of Phase I study
18 Jan 2022 //
PRNEWSWIRE
ImmVira Launches Pilot-scale Production Line
21 Jul 2021 //
CONTRACT PHARMA
ImmVira completed the first dosing for Phase II of MVR-T3011
14 Jun 2021 //
PRNEWSWIRE
ImmVira completed first dosing for Phase II of MVR-T3011 in the U.S. and China
12 Jun 2021 //
PRNEWSWIRE
ImmVira completed the first dosing for Phase II of MVR-T3011 in the US and China
11 Jun 2021 //
PRNEWSWIRE
Superior safety and efficacy of zanubrutinib compared to ibrutinib
11 Jun 2021 //
PRNEWSWIRE
ImmVira completed the first dosing for Phase II of MVR-T3011 in the US and China
11 Jun 2021 //
PRNEWSWIRE
Superior safety and efficacy of zanubrutinib compared to ibrutinib
11 Jun 2021 //
PRNEWSWIRE
AACR 2021-ImmVira presents the preclinical study results of MVR-T3011
20 Apr 2021 //
PRNEWSWIRE
AACR 2021-ImmVira presents the preclinical study results of MVR-T3011
20 Apr 2021 //
PRNEWSWIRE
AACR 2021-ImmVira presents the preclinical study results of MVR-T3011
19 Apr 2021 //
PRNEWSWIRE
AACR 2021-ImmVira presents the preclinical study results of MVR-T3011
19 Apr 2021 //
PRNASIA
ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO
08 Apr 2021 //
PRNEWSWIRE
ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO
08 Apr 2021 //
PRNASIA
ImmVira Announces Series C Financing with Leading Specialist Investors
31 Dec 2020 //
PRNASIA
ImmVira Announces Series C Financing with Leading Specialist Investors
30 Dec 2020 //
PRNEWSWIRE
ImmVira Announces Series C Financing with Leading Specialist Investors
30 Dec 2020 //
PRNASIA
ImmVira Announces US$10M Strategic Series B Plus Financing with SIIC Capital
24 Sep 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.